Figure 2 Decision tree showing scenarios in which OCT and aflibercept are either available/unavailable for the clinical management of macular oedema secondary to CRVO. Note that all patients enter the pathway with “prior testing” as detailed in Figure 1 (see also text on decision analytic). Abbreviations: MO, macular oedema; CRVO, central retinal vein occlusion; OCT, optical coherence tomography; VA, visual acuity; IV, intravitreal; NV, neovascularisation; VEGF, vascular endothelial growth factor; PRP, pan-retinal photocoagulation
Figure 2 Decision tree showing scenarios in which OCT and aflibercept are either available/unavailable for the clinical management of macular oedema secondary to CRVO. Note that all patients enter the pathway with “prior testing” as detailed in Figure 1 (see also text on decision analytic). Abbreviations: MO, macular oedema; CRVO, central retinal vein occlusion; OCT, optical coherence tomography; VA, visual acuity; IV, intravitreal; NV, neovascularisation; VEGF, vascular endothelial growth factor; PRP, pan-retinal photocoagulation
1310-OCT-FinalDAP-AgreedRedactions-accessible.docx